Humulin Nph

Humulin Nph is a recombinant human insulin (rDNA) formulated as an intermediate‑acting injectable solution for subcutaneous administration. It contains insulin human in an NPH (neutral protamine Hagedorn) preparation, providing a prolonged onset of action and a duration of up to 24 hours. The product is authorized in the European Union as a prescription‑only medication and is used as part of a comprehensive diabetes treatment plan together with diet, exercise and therapies.

Humulin Nph is indicated for the management of hyperglycemia in adults with diabetes when basal insulin coverage is required.

- Type 1 diabetes mellitus as part of a basal‑bolus insulin regimen. - Type 2 diabetes mellitus when oral agents or other injectables do not achieve target glucose levels. - Adjunct therapy during pregnancy or lactation under specialist supervision, when basal insulin is needed. - Use in combination with rapid‑acting insulin analogues to provide basal insulin support. - Adjustment of basal insulin dose in response to changes in diet, physical activity, or illness.

Adverse reactions to Humulin Nph may vary in frequency and severity; they are typically categorized as common or serious.

Common: - Hypoglycemia, especially if meals are missed or dosing is excessive. - Injection site reactions such as redness, swelling, or itching. - Weight gain associated with improved glycemic control. - Lipodystrophy at the injection site, presenting as lipoatrophy or lipohypertrophy. - Transient blurred vision during periods of rapid glucose change. - Mild gastrointestinal discomfort such as nausea or abdominal fullness.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions including urticaria, angioedema, or anaphylaxis. - Insulin antibody formation causing unpredictable glucose control. - Edema or fluid retention, particularly in patients with cardiac or renal impairment.

When prescribing Humulin Nph, clinicians should evaluate patient-specific factors and monitor for conditions that may affect insulin therapy.

- Renal or hepatic impairment may alter insulin clearance; dose adjustments may be required. - Elderly patients are at higher risk for hypoglycemia and should be started on lower doses. - Pregnancy and lactation status should be confirmed; insulin is the preferred agent but dosing must be individualized. - Concurrent illness, infection, or stress can increase insulin requirements and precipitate hyperglycemia. - Patients with a history of severe allergic reactions to insulin or protamine should avoid this product. - Regular monitoring of blood glucose and HbA1c is essential to assess therapeutic effectiveness.

Humulin Nph may interact with other medicines that influence glucose metabolism, insulin action, or protein binding.

Avoid: - Concurrent use of other rapid‑acting insulins or insulin analogues without proper dose adjustment, which can cause severe hypoglycemia. - Beta‑blockers that mask hypoglycemia symptoms, increasing the risk of unnoticed low blood glucose. - High‑dose corticosteroids that markedly raise blood glucose, potentially overwhelming basal insulin coverage.

Use with caution: - Oral antidiabetic agents such as sulfonylureas or meglitinides, which can potentiate hypoglycemia. - Thiazide diuretics that may increase blood glucose levels, requiring closer monitoring. - Alcohol consumption, especially in excess, as it can cause unpredictable glucose fluctuations.